HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis.
about
NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic ManifestationsSignificance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinomaHepatitis C genotype 4: The past, present, and futurePathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogenReview article: HCV genotype 3 – the new treatment challengeOrigin of hepatitis C virus genotype 3 in Africa as estimated through an evolutionary analysis of the full-length genomes of nine subtypes, including the newly sequenced 3d and 3eGlobal epidemiology and burden of HCV infection and HCV-related disease.Hepatitis C genotype 3 disease.APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.Consensus Statement of HCV Task Force of the Indian National Association for Study of the Liver (INASL). Part II: INASL Recommendations for Management of HCV in India.Viral hepatitis and hepatocellular carcinoma: etiology and managementInterferon-free treatments in patients with hepatitis C genotype 1-4 infections in a real-world settingA Circulating MicroRNA Signature Capable of Assessing the Risk of Hepatocellular Carcinoma in Cirrhotic Patients.Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus.Hepatocellular carcinoma in nonalcoholic fatty liver: role of environmental and genetic factors.Differences in HCV viral decline between low and standard-dose pegylated-interferon-alpha-2a with ribavirin in HIV/HCV genotype 3 patientsAll-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.Hepatitis C virus-induced hepatocellular carcinomaA Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin.Hepatitis C virus infection: Are there still specific problems with genotype 3?Hepatitis C genotype influences post-liver transplant outcomesHCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV.Hepatitis C virus-related hepatocellular carcinoma: An insight into molecular mechanisms and therapeutic strategiesClinical Features and Outcomes of Patients With Genotype 3 Hepatitis C Virus Infection in Korea: A Retrospective Observational Study.Demographic profile, host, disease & viral predictive factors of response in patients with chronic hepatitis C virus infection at a tertiary care hospital in north IndiaDaclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).Treatment of patients with genotype 3 chronic hepatitis C--current and future therapies.The predictive value of steatosis in hepatitis C virus infection.Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3.Is genotype 3 of the hepatitis C virus the new villain?Treatment of hepatitis C virus genotype 3-infection.Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection.Concurrent Obesity, Diabetes, and Steatosis Increase Risk of Advanced Fibrosis Among HCV Patients: A Systematic Review.Dual daclatasvir and sofosbuvir for treatment of genotype 3 chronic hepatitis C virus infection.Hepatitis C virus: how to provide the best treatment with what I have.Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions.Genotype 3 Infection: The Last Stand of Hepatitis C Virus.Literature review of the distribution of hepatitis C virus genotypes across Europe.Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therpy: a real-life study.Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.
P2860
Q26745576-3B23EB5F-956F-4B24-8050-97F368FA7423Q26773251-FDDA0F53-FFFE-4748-885A-6AB56A70082EQ26775815-BF166533-1AA5-4D12-9B2E-5AABDEDA71F2Q26861095-E8EF207B-A457-4675-96CE-4747BE3FC03BQ26864571-75FF88FD-4CBD-420C-A0E8-21F6FC9E8BA2Q28655567-32D841BF-5D95-41F0-BC88-4A16354100F0Q30240220-A71B341B-93EF-4975-8327-EF9773336A3EQ30244065-9733642A-6886-45F8-9B48-AD5E0A687098Q30250088-BE4A8A13-8301-4B46-8208-B25DFF742F03Q30417045-2393186A-6A9D-4E16-9494-FB78BCA05F8CQ33593219-22804489-0404-45A6-8DDA-97976E8D098BQ33646482-002F0DD1-3574-4408-B50B-EAC0533B5117Q33674511-192A2098-682A-4394-B44B-3B6AB9F3999DQ33922932-D8CDBABB-38AF-41E3-AD05-7C0FA0FB8FE8Q34255487-707C2A9D-0041-48EA-9C6D-0F81137DDC43Q34473823-9AEB7A06-233A-4F30-9A5A-D7210DD8E885Q35538245-DBAC23EB-80DD-4D61-B2DB-6CCB06303A6AQ35824057-96EE6E2F-D55A-4533-B7A0-243658C294BDQ35962849-A72DF0A8-65F0-4A5F-BFA3-4656970E06F1Q36269670-F52F5D76-D176-4B32-85ED-18D6A7F76980Q36354472-F9450D63-A19F-4B55-9371-73ED69E50C2FQ36399139-C45BA776-5F56-45A7-A38E-694396FE95EAQ36561567-6F98AC41-EFC9-4AD1-8D79-47FCC405BF85Q36581068-B49115A9-11B4-4A35-A649-DFF4775A7979Q36966151-B58E5835-E9CC-40B3-92FD-84D637F1EB84Q37349005-C8D16164-9E53-4EA8-9546-E13EADAE7E52Q37972774-E466A809-272B-4132-982A-4E44F3B9F800Q38085061-F039E172-684B-456C-BA17-A734D8D0A64BQ38134774-FC97B8F4-3107-48EC-BF5B-141B53CF9D07Q38155123-8C229620-A69A-4B54-B53F-1EA57DA7B653Q38174244-E90A320E-FE5F-48D8-BFF7-20EF2830A91DQ38517530-1B7C9ED5-8A3B-4D7D-8B28-B6D76313F738Q38542209-196FB166-0FAF-4DE2-B215-6552B37BE10FQ38631256-97D53EA2-A492-4097-8833-5336CEFC4DD9Q38685580-1155DA36-B25D-45C7-A00A-08AB5952E492Q38728564-79A88768-4B32-48D3-BE06-29E08E68E2BFQ38772047-FB984EE1-2A68-436F-A6CD-307532278AB5Q38832756-AA86F2DC-3433-4F79-B336-60FE867DDE0EQ38865530-0AE57F42-053F-4F4F-B9B5-24673587EE0CQ38972499-519976A2-A56C-4060-BFDA-5D7064D7359D
P2860
HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
HCV genotype 3 is associated w ...... ith ongoing viral C cirrhosis.
@en
HCV genotype 3 is associated w ...... ith ongoing viral C cirrhosis.
@nl
type
label
HCV genotype 3 is associated w ...... ith ongoing viral C cirrhosis.
@en
HCV genotype 3 is associated w ...... ith ongoing viral C cirrhosis.
@nl
prefLabel
HCV genotype 3 is associated w ...... ith ongoing viral C cirrhosis.
@en
HCV genotype 3 is associated w ...... ith ongoing viral C cirrhosis.
@nl
P2093
P2860
P1476
HCV genotype 3 is associated w ...... ith ongoing viral C cirrhosis.
@en
P2093
A Mahmoudi
G Nkontchou
J-C Trinchet
M Beaugrand
M Lhabadie
P2860
P304
P356
10.1111/J.1365-2893.2011.01441.X
P577
2011-10-01T00:00:00Z